Here’s what our users and the scientific literature say about dosing NMN and Resveratrol.

Photo by Justin Novello on Unsplash

DISCLAIMER: The following is not intended as medical advice, as always please consult your medical practitioner.

VERSO® is not affiliated with any of the below referenced studies. The authors of these studies are not affiliated with VERSO®.

While we can’t tell you what to take, we can share what other users experiences are, and point out what the scientific literature says.

USER BASED FEEDBACK:

Based on our discussions with our users, here’s what they say works for them:

DOSAGE IN THE SCIENTIFIC LITERATURE

While NMN doesn’t have many human trials, some data can be extrapolated from animal models to humans. Resveratrol on the other hand does have much more human trial data:

NMN:

The majority of animal studies used high doses, around 500 mg/kg of body weight and injected in to the abdominal region, which makes it difficult to translate into humans.

For studies that used oral administration in animal models, the results were consistently dose dependent. On the low end, the oral administration was 100 mg/kg bodyweight, human equivalent of 8 mg/kg of body weight – in a 180lb person this would be about 650 mg/day of NMN. The mitigation of age associated physiological decline was much more robust at a higher dose of 300 mg/kg of body weight, human equivalent of 24 mg/kg of body weight – in a 180lb person this would be about 2,000 mg/day of NMN.

The recent human safety trial on NMN used oral doses of 100, 250, and 500 mg. Downstream metabolites of NMN: MNA, 2Py, and 4Py were measured across time after administration. The 2Py and 4Py metabolites appeared to elicit a non-linear dose response, wherein the 100 mg/day and 250 mg/day dosage yielded similar metabolite levels, and 500 mg/day produced much higher levels of downstream metabolites than the other dosages. Levels continued to rise up to the end of the five hour observation window.

source: https://www.jstage.jst.go.jp/article/endocrj/67/2/67_EJ19-0313/_html/-char/en

RESVERATROL:

Obese, but otherwise healthy men were treated with 150 mg/day for 30 days. Decreased blood pressure, improved circulating glucose, insulin and triglyceride concentrations were observed among other improved health markers.

Multiple studies in people with T2D (type two diabetes) show that a treatment of resveratrol ranging from 1,000 – 2,000 mg/day significantly decreases blood pressure, circulating insulin, while improving insulin sensitivity and increasing HDL (high-density lipoprotein, “good” cholesterol) levels.

Patients with NAFLD (nonalcoholic fatty liver disease) who were given 300 mg/day or 500 mg/day of resveratrol showed a decrease in serum LDL (low-density lipoprotein) levels, decreased inflammation markers, and improved insulin sensitivity.

Patients undergoing statin treatment for cardiovascular disease prevention took 350 mg/day for six months saw a decrease in LDL, oxidized LDL, and ApoB (apolipoprotein B). After the initial six month resveratrol treatment patients received 700 mg/day for another six months, resulting in a decrease in inflammatory markers, and an increase in an anti-inflammatory marker.

Healthy adults (aged 50-75 years) who took 200 mg/day of resveratrol for 26 weeks improved the ability to complete memory tasks.

In a phase 2 clinical trial for the treatment of AD (Alzheimer’s disease), patients diagnosed with AD were given 500 mg/day, with dose-escalation by 500 mg increment every 13 weeks, ending with 2,000 mg/day. Patients saw improvements in mental examination status scores, improved cerebrospinal fluid amyloid-beta levels (a biomarker for AD), and lowered cerebrospinal fluid matrix metalloproteinase 9 (a neuroinflammation mediator).

SUMMARY OF THE SCIENTIFIC LITERATURE ON DOSAGE:

NMN:

RESVERATROL:

Note: Dosage written in the for of X mg/kg is referring to a weight based dosage, meaning X mg per kg of body weight.

Leave a Reply

Your email address will not be published. Required fields are marked *

Sign up to our newsletter!